-
GLYX-13 and GFPA NMDA Receptor Modulators
Burgdorf, J., Zhang, X.L., Weiss, C., Matthews, E., Disterhoft, J.F., Stanton, P.K., and Moskal, J.R., 2009. The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging, in press.
Haring, R., Stanton, P.K., Scheideler, M., and Moskal, J.R., 1991. Glycine-like modulation of NMDA receptors by a monoclonal antibody that enhances long-term potentiation. J. Neurochem. 57, 323-332. First report showing a monoclonal antibody enhancing learning and memory formation and its mechanism of action
Moskal, J.R, Kuo, A.G, Weiss, C., Kelso, S., O'Connor Hanson, A., Wood, P.L., and Disterhoft, J.F., 2005. GLYX-13: monoclonal antibody-derived peptides that act as partial agonists at the glycine site of the N-methyl-D-aspartate receptor. Neuropharmacology 49, 1077-1087. Describes the conversion of a monoclonal antibody into a small peptide mimetic with cognitive enhancing properties
Moskal, J.R., Yamamoto, H., and Colley, P.A., 2001. The use of antibody engineering to create novel drugs that target N-methyl-D-aspartate receptors. Current Drug Targets 2, 331-345. Review of GLYX-13 & its creation from a monoclonal antibody with NMDAR glycine site-specificpartial antagonist properties
Moskal, J.R. and Schaffner, A.E., 1986. Monoclonal antibodies to the dentate gyrus: Immunocytochemical characterization and flow cytometric analysis of hippocampal neurons bearing unique cell-surface antigen. J. Neurosci. 6, 2045-2053. Seminal publication of original monoclonal antibody work
Stanton, P.K., Sarvey, J.M., and Moskal, J.R., 1987. Inhibition of the production and maintenance of long-term potentiation in rat hippocampal slices by a monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 84, 1684-1688. First report showing modulation of learning and memory using a monoclonal antibody
Thompson, L.T., Moskal, J.R., and Disterhoft, J.F., 1992. Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine. Nature 359, 638-641. First report showing monoclonal antibody enhancement of learning and memory in an animal model
Wood, P.L., Mahmood, S.A., and Moskal, J.R., 2008. Antinociceptive action of GLYX-13: an NMDA receptor glycine site partial agonist. Neuroreport 19, 1059-61. First publication of GLYX-13 general NMDA properties relative to known other NMDA programs; and in vivo antinociceptive models comparable to FDA approved neuropathic pain drug, gabapentin
Zhang, X.L., Sullivan, J.A., Moskal, J.R., and Stanton, P.K., 2008. A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 55, 1238-1250. First evidence of GLYX-13 unique mechanism of action showing ability to increase LTP and decrease LTD
Other NMDA Receptor Modulator References
Burgdorf, J., Knutson, B., Panksepp, J., and Shippenberg, T.S., 2001. Evaluation of rat ultrasonic vocalizations as predictors of the conditioned aversive effects of drugs. Psychopharmacology 155, 35-42.
Cryan, J. and O’Leary, O., 2010. A glutamate pathway to faster-acting antidepressants? Science 329, 913-914.
de Bruin, N.M., Ellenbroek, B.A., Cools, A.R., Coenen, A.M., and van Luijtelaar, E.L., 1999. Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology 142, 9-17.
Diazgranados, N., Ibrahim, L., Brutsche, N., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W., Quezado, Z., Luckenbaugh, D., Salvadore, G., Machado-Vieira, R., Manji, H., and Zarate, C., 2010. A randomized add-on trial of an NMDA antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 8, 793-802.
Du, J., Machado-Vieira, R., Maeng, S., Martinowich, K., Manji, H., and Zarate, C., 2006. Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. Drug Discovery Today: Therapeutic Strategies 4, 519-526.
Frederick, R. (Host) 2010. "Fast-Acting Antidepressant." 959 Data Supplement -- Podcast interview. Duman, R. Science, August 20 http://www.sciencemag.org/cgi/content/full/329/5994/959/DC2
Garcia, L.S., Comim, C.M., Valvassori, S.S., Reus, G.Z., Barbosa, L.M., Andreazza, A.C., Stertz, L., Fries, G.R., Gavioli, E.C., Kapczinski, F., and Quevedo, J., 2008. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 32, 140-144.
Li, N., Lee, B., Liu, R., Banasr, M., Dwyer, J., Iwata, M., Li, X., Aghajanian, G., and Duman, R., 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964.
Maeng, S., Zarate, C., Du, J., Schloesser, R., McCammon, J., Chen, G., and Manji, H., 2008. Cellular mechanisms underlying the antidepressant effects of ketamine. Biol Psychiatry 63, 349-352.
Skolnick, P., Popik, P., Trullas, R., 2009. Glutamate-based antidepressants: 20 years on, Trends Pharmacol Sci. 30, 563-569. Reviews NMDA receptor hypothesis in depression, including multiple studies providing clinical proof-of-concept data for a number of NMDAR molecules.
van der Kam, E.L., DeVry, J., and Tzschentke, T.M., 2009. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates ketamine and heroin reward as assessed by acquisition, extinction, and reinstatement of conditioned place preference in the rat. Eur. J. Pharmacol. 606, 94-101.
Wang, J., Lanfranco, M., Gibb, S., Yowell, Q., Carnicella, S., and Ron, D., 2010. Long-lasting adaptations of the NR2B-containing NMDA receptors in the dorsomedial striatum play a crucial role in alcohol consumption and relapse. The Journal of Neuroscience 30, 10187-10198.